Merrill maintains Angiotech at buy

Angiotech Pharmaceuticals Inc. was maintained by Merrill Lynch analyst Hari Sambasivam at a buy. The company and its marketing partner, Boston Scientific, received a favorable ruling in a patent dispute in the Netherlands related to the paclitaxel (or Hunter) patent. The court enjoined Sahajanand from selling its stent in the Netherlands and ordered damages to be paid to Angiotech. Shares of the Salt Lake City biopharmaceutical company were up 11 cents, or 0.66%, at C$16.67 on volume of 57,764 shares versus the three-month running average of 199,210 shares. (Toronto: ANP CN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.